Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Placebo nebuliser solution
DRUG
2 trials
Sponsors
GlaxoSmithKline
, University of Giessen
Conditions
COVID-19 Pneumonia
Idiopathic Pulmonary Fibrosis
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Phase 1
First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
Completed
NCT02612051
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
Start: 2015-12-04
End: 2016-06-02
Updated: 2017-05-01
Phase 2
GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia
Completed
NCT04569877
University of Giessen
COVID-19 Pneumonia, Severe Acute Respiratory Syndrome (SARS) Pneumonia
Start: 2020-09-24
End: 2022-09-20
Updated: 2023-05-10
Related Papers
Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avß6 integrin inhibitor
2019-09-28
3 citations
Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.
2018-03-12
44 citations
The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis
Respiratory Research
2018-02-06
31 citations